Biotech Values

[DewDiligence]

Not sure patients would agree but from a clinician standpoint I would think even a 5% delta [SVR] would warrant the additional drug(s). Thoughts anyone?

Provided that you’re calculating SVR on an ITT basis (so the SVR number incorporates the effect of premature discontinuations), I concur that a 5% SVR delta warrants adding a drug to the cocktail. In the case of ribavirin, specifically, the cost delta is not a major concern insofar as ribavirin is available as a generic.